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BACKGROUND: Depression is associated with adverse
prognosis in cardiac patients, warranting the availability
of brief and valid instruments to identify depressed
patients in clinical practice.
OBJECTIVES: We examined whether the two-item
Patient Health Questionnaire (PHQ-2) was associated
with adverse events in percutaneous coronary interven-
tion (PCI) patients treated with paclitaxel-eluting stent-
ing (using the continuous score and various cutoffs),
overall and by gender.
DESIGN: Prospective follow-up study.
PARTICIPANTS: Consecutive PCI patients (n=796) seen
at a university medical centre.
MEASUREMENTS: PHQ-2 at baseline. The study end-
point was an adverse event, defined as a combination of
death or non-fatal myocardial infarction (MI) at follow-up
(mean of 1.4 years).
RESULTS: At follow-up, 47 patients had experienced
an adverse event. Using the continuous score of the
PHQ-2 and the recommended cutoff ≥3, depressive
symptoms were not associated with adverse events
(ps>0.05). Using a cutoff ≥2, depressive symptoms
were significantly associated with adverse events (HR:
1.89; 95% CI: 1.06–3.35) and remained significant in
adjusted analysis (HR: 1.90; 95% CI: 1.05–3.44). Depres-
sive symptoms were associated with an increased risk of
adverse events in men (HR: 2.69; 95% CI: 1.36–5.32) but
not inwomen (HR: 0.76; 95%CI: 0.24–2.43); these results
remained in adjusted analysis.
CONCLUSIONS: Depression screening with a two-item
scale and a cutoff score of ≥2 was independently
associated with adverse events at follow-up. The PHQ-
2 is a brief and valid measure that can easily be used
post PCI to identify patients at risk for adverse health
outcomes.
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INTRODUCTION
Depression is a common co-morbid disorder of coronary artery
disease (CAD)1 associated with adverse health outcomes2–7. Not
onlymajor depressive disorders but also subclinical levels increase
the risk of poor prognosis8,9. Different depressive symptoms may
also exert differential prognostic effects9,10. Depression as a
prognostic marker has primarily been studied post myocardial
infarction (MI), although we previously showed that depressive
symptoms are associated with prognosis post percutaneous
coronary intervention (PCI)10. Knowledge of the potential patho-
genic influence of depressive symptoms in PCI patients is
important for secondary prevention due to the dramatic increase
and projected increase in PCI procedures worldwide11.
A recent science advisory from the American Heart Associ-
ation advocates routine screening for depression in clinical
practice using the two-item Patient Health Questionnaire
(PHQ) followed by the nine-item PHQ, if screening positive on
one or both items of the PHQ-212. Both measures are feasible
to use as screening instruments in clinical practice due to their
brevity13–15. In patients with CAD and chronic heart failure
(CHF), the PHQ-2 has been used in research on clinical
depression, quality of life and heart rate variability6,15–21, but
its prognostic value is as yet to be determined in cardiac
patients. By contrast, two studies have investigated the
prognostic value of the PHQ-9. Major but not minor depression
was associated with a two-fold risk of mortality in CHF22,
whereas depression was associated with a range of health
outcomes including mortality post MI23. The CHF study failed
to find a gender differential prognostic effect for depression22.
The PHQ-2 measures the two cardinal symptoms of a
clinical diagnosis of depression (i.e., “Little interest or pleasure
in doing things”; “Feeling down, depressed, or hopeless”)15,24.
Given the current debate on confounding of depression by
CAD severity4, a more sound strategy might be to restrict the
studying of the role of depression in cardiac prognosis to these
cardinal symptoms. Hence, the PHQ-2 may not only be
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superior due to its brevity, but also due to it being less prone to
confounding by disease severity compared to the PHQ-9, as the
PHQ-9 contains items that are common in cardiac patients
(e.g., difficulty sleeping). Even though a cutoff ≥3 on the PHQ-
2 is recommended24, data from the Heart and Soul study
indicate that a cutoff ≥2 represents an optimal balance between
sensitivity and specificity for identifying major depression in
cardiac patients, and is comparable to the PHQ-925. Research is
warranted to investigate whether the adoption of different cutoffs
has differential prognostic value in cardiac patients15,22.
We examined (1) whether the PHQ-2, using a continuous
score versus different cutoff scores, is associated with prognosis
in PCI patients and (2) whether the PHQ-2 has differential
prognostic value in men versus women.
METHODS
Patients and Design
Consecutive patients treatedwith PCI between 15 February 2005
to 14 February 2006 in the Erasmus Medical Center Rotterdam,
The Netherlands, comprised the sample for the current study.
The paclitaxel-eluting stent was used as the default strategy in
our institution during this period. All patients were advised to
take clopidogrel for a minimum of 6 months post procedure.
Survival status for all patients was obtained 30 days after the
index procedure; all surviving patients (referred to as baseline in
the remainder of the article) were approached by mail and asked
to complete the PHQ-215. Assessment 30 days post PCI was
chosen due to logistic reasons, but also due to concerns that
depression assessed too close to the index event may reflect
underlying somatic disease rather than depression4,26. If the
questionnaire was not returned within 3 weeks, a reminder was
sent together with a new questionnaire.
The study protocol was approved by the medical ethics
committee of the Erasmus Medical Center. All patients provided
written informed consent, and the study was carried out in
accordance with the Declaration of Helsinki.
MATERIALS
Demographic and Clinical Variables
Demographic variables included gender and age. Information on
clinical variables, e.g., indication for PCI, multi-vessel disease,
previous MI, previous PCI, previous coronary artery bypass graft
surgery (CABG), hypertension, hypercholesterolemia, diabetes
and cardiac medication (i.e., aspirin, calcium antagonists, beta-
blockers, ACE inhibitors, statins, diuretics, clopidogrel and
heparin), were obtained from the patients’ medical records.
Smoking status was assessed by means of self-report.
Depression
Depressive symptoms were assessed with the PHQ-215,24. The
two symptoms assessed in this questionnaire ("Little interest
or pleasure in doing things"; "Feeling down, depressed or
hopeless") represent the cardinal symptoms of a clinical
diagnosis of depression, according to the diagnostic criteria
for clinical depression as listed in the Diagnostic and Statisti-
cal Manual of Mental Disorders IV-TR. The items are rated on a
4-point Likert scale from 0 (not at all) to 3 (nearly every day),
and the total score range is 0–6. The PHQ-2 is a valid and
internally consistent instrument (Cronbach’s alpha=0.83)24. A
cutoff ≥3 has been proposed to present the most optimal
balance between sensitivity and specificity for major depressive
disorder and any depressive disorder24, although in cardiac
patients a cutoff ≥2 seems to present the best balance25.
Study Endpoint
The study endpoint (adverse event) was defined as a combination
of death (all-cause) or non-fatal MI. Follow-up was complete for
all patients, and the mean follow-up period was 1.4 years.
Survival status was obtained from municipal civil registries.
Reinfarction was diagnosed by recurrent symptoms and/or new
electrocardiographic changes in association with increases in
creatine kinase and creatine kinase myoglobin levels of >3 times
the upper normal limit27. A combined endpoint was used due to
the small number of events and the fact that combined outcomes
are commonly used in cardiovascular outcome studies. As the
principal regional cardiac referral center, repeat procedures are
normally performed at our institution and recorded prospectively
in our database. However, given that several patients are referred
fromhospitals in the area, and in order to ensure that all MIs and
repeat procedures were captured, patients were asked via a
postal survey at 1-year if they had experienced an event during
the follow-up period. This information was verified against the
medical records, and if necessary via general practitioners or
referring cardiologists.
Statistical Analysis
Differences on nominal variables were compared with the chi-
square test and on continuous variables with Student’s t-test.
Unadjusted and adjusted Cox proportional hazard regression
analyses were used to examine the impact of depressive
symptoms on adverse clinical events. A priori based on the
literature, the covariates gender, age, multi-vessel disease,
cardiac history (i.e., previous MI, PCI or CABG), hypertension,
hypercholesterolemia, diabetes, smoking, ACE inhibitors and
statins were selected for inclusion in all multivariable analyses.
In secondary analyses, we also included the interaction effect of
depressive symptoms by gender to examine whether the PHQ-2
had a differential prognostic effect in men compared to women.
We tested the statistical significance of differences in proportions
between depressed and non-depressed males and females28 and
χ2 differences, using Cohen’s effect size index w29. According to
the thresholds for the effect size statistic w for differences
between proportions, an effect size of 0.10 is considered small,
0.30 medium and 0.50 large. All tests were two-tailed (p-value<
0.05); for Cox proportional hazard regression analyses, hazard
ratios (HR) and their corresponding 95% confidence intervals (CI)
are reported. All data were analyzed using SPSS 17.0 for
Windows (SPSS Inc., Chicago, IL).
RESULTS
Non-responders Versus Responders on Baseline
Characteristics
Of 1,238 eligible patients treated with PCI in the study period,
66 died within 30 days. The remaining 1,172 patients were
1038 Pedersen et al.: Prognostic Value of the PHQ-2 Post PCI JGIM
asked to participate in the study, of which 870 (74.2%) agreed.
Responders (n=870) were more likely to be older (mean 62.7±
11.5 versus 60.2±13.4; p=0.006), to have hypercholesterol-
emia (81.0% versus 71.9%; p=0.001) and to be prescribed
aspirin (92.6% versus 87.1%; p=0.005) compared to non-
responders (n=302). No other statistically significant differ-
ences were found between responders and non-responders on
baseline characteristics. Analyses are based on 796 patients
who had completed the PHQ-2.
Baseline Characteristics of the Sample
The mean depression score on the PHQ-2 was 1.01±1.42 at
baseline. The prevalence of depressive symptoms was 45.9%
(365/796) for cutoff ≥1, 30.2% (240/796) for cutoff ≥2 and
11.9% (95/796) for cutoff ≥3.
Baseline characteristics stratified by depressive symptoms
using the cutoff ≥225 and ≥324 on the PHQ-2 are presented in
Table 1. Using the cutoff ≥2, depressed patients were more
likely to have had a previous MI, previous PCI, hypercholes-
terolemia, diabetes, to be smoking, and to be prescribed ACE
inhibitors and statins. No other statistically significant differ-
ences were found between depressed and non-depressed
patients on baseline characteristics.
Using the cutoff ≥3, depressed patients were more likely to
have had a previous MI and to be prescribed ACE inhibitors
compared to non-depressed patients. No other statistically
significant differences were found between depressed and non-
depressed patients on baseline characteristics.
Depressive Symptoms and Adverse Events
There were 47 adverse events (deaths=35; MIs=12). In unad-
justed analysis, the continuous PHQ-2 depression score was
not significantly related to adverse events at follow-up (HR:
1.15; 95% CI: 0.97–1.36; p=0.12). The cutoff ≥3 on the PHQ-2
was also not significantly associated with adverse events (HR:
1.27; 95% CI: 0.57–2.83; p=0.57). However, with a cutoff ≥2,
the incidence of adverse events was significantly higher in
Table 1. Baseline Characteristics for the Total Sample and Stratified by Depressive Symptoms (PHQ-2 Cutoff ≥2 and ≥3)*
Total PHQ-2 cutoff ≥2 PHQ-2 cutoff ≥3
n=796 Depressed
(n=240)
Non-depressed
(n=556)
p Depressed
(n=95)
Non-depressed
(n=701)
P
Demographics
Male gender 574 (72.1) 164 (68.3) 410 (73.7) 0.14 64 (67.4) 510 (72.8) 0.33
Age, mean ±SD 62.5±11.5 62.2±11.9 62.7±11.4 0.59 63.8±12.0 62.4±11.4 0.25
Clinical
Indication for PCI (MI) 264 (33.2) 84 (35.0) 180 (32.4) 0.52 34 (35.8) 230 (32.8) 0.64
Multi-vessel disease 379 (47.6) 109 (45.4) 270 (48.6) 0.46 47 (49.5) 332 (47.4) 0.78
Previous MI 216 (27.1) 79 (32.9) 137 (24.6) 0.02 38 (40.0) 178 (25.4) 0.004
Previous PCI 223 (28.0) 82 (34.2) 141 (25.4) 0.01 29 (30.5) 194 (27.7) 0.65
Previous CABG 71 (8.9) 27 (11.3) 44 (7.9) 0.17 13 (13.7) 58 (8.3) 0.12
Hypertension† 343 (43.1) 105 (43.8) 238 (42.8) 0.87 40 (42.1) 303 (43.2) 0.92
Hypercholesterolemia‡ 648 (81.4) 210 (87.5) 438 (78.8) 0.005 82 (86.3) 566 (80.7) 0.24
Diabetes§ 137 (17.2) 53 (22.1) 84 (15.1) 0.02 22 (23.2) 115 (16.4) 0.14
Smoking□ 202 (25.4) 76 (31.7) 126 (22.7) 0.01 28 (29.5) 174 (24.8) 0.39
Medication
Aspirin 742 (93.2) 229 (95.4) 513 (92.3) 0.14 89 (93.7) 653 (93.2) 1.00
Calcium antagonists 14 (1.8) 3 (3.1) 11 (2.0) 0.67 1 (1.1) 13 (1.9) 0.89
Beta-blockers 499 (62.7) 155 (64.6) 344 (61.9) 0.52 57 (60.0) 442 (63.1) 0.64
ACE inhibitors 295 (37.1) 108 (45.0) 187 (33.6) 0.003 45 (47.4) 250 (35.7) 0.04
Statins 583 (73.2) 189 (78.8) 394 (70.9) 0.03 73 (76.8) 510 (72.8) 0.47
Diuretics 76 (9.5) 25 (10.4) 51 (9.2) 0.68 11 (11.6) 65 (9.3) 0.60
Clopidogrel 796 (100) 240 (100) 556 (100) 1.00 95 (100) 701 (100) 1.00
Heparin 127 (16.0) 43 (17.9) 84 (15.1) 0.38 12 (12.6) 115 (16.4) 0.43
*Results are presented as numbers (%), unless otherwise indicated
MI = myocardial infarction; PCI = percutaneous coronary intervention; CABG = coronary artery bypass graft surgery
†140/90 mmHg or being treated for hypertension
‡ ≥240 mg/dl or being treated for hypercholesterolemia
§Being treated for diabetes
□Based on the patient’s self-report
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Figure 1. Incidence of adverse events stratified by depressive
symptomatology (PHQ-2 cutoff ≥2)*.
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depressed versus non-depressed (8.8% versus 4.7%; HR: 1.89;
95% CI: 1.06–3.35; p=0.03) (Fig. 1).
Given that neither the continuous PHQ-2depression score nor
the cutoff ≥3 was significantly associated with adverse events in
unadjusted analysis, adjusted analysis was only performed for
the cutoff ≥2. Depressive symptoms (HR: 1.90; 95% CI: 1.05–
3.44; p=0.03) remained an independent correlate of adverse
events at follow-up in adjusted analysis (Table 2).
To further disentangle the relationship between depressive
symptoms and adverse events, we examined the separate
effects of item 1 (i.e., “Little interest or pleasure in doing
things”) and item 2 (i.e., “Feeling down, depressed, or hope-
less”) on adverse events. Labeling a response from 1–3 as a
positive response, item 2 (HR: 2.05; 95% CI: 1.16–3.64;
p=0.01) was significantly associated with adverse events, and
there was a trend for item 1 (HR: 1.74; 95% CI: 0.98–3.09;
p=0.06), suggesting that the relationship between depressive
symptoms and prognosis was driven by both items, but to a
greater extent by anhedonia.
Differential Prognostic Effect of the PHQ-2 onGender
To examine whether the cutoff ≥2 on the PHQ-2 had a
differential prognostic effect in men and women, we ran
secondary analyses including the interaction effect of depres-
sive symptoms by gender together with the main effects. The
number of adverse events at follow-up in men was 33 and 14
in women. In unadjusted analysis, there was a clear trend for
the interaction effect (HR: 3.52; 95% CI: 0.92–13.52; p=0.06).
Performing separate analyses in male and female patients, the
incidence of adverse events was higher in depressed versus
non-depressedmen (10.4%versus 3.9%;HR: 2.69; 95%CI: 1.36–
5.32; p=0.005), but not in depressed versus non-depressed
women (5.3% versus 6.8; HR: 0.76; 95% CI: 0.24–2.43;
p=0.64). The difference in proportions between depressed versus
non-depressed men who experienced an event was 6.5 (95% CI:
1.1–11.5), with Cohen’s effect size w=0.13 indicating a small
effect. By comparison, the difference in proportions was 1.6 (95%
CI −4.8–8.1) in depressed versus non-depressed women. An
effect size was not calculated for women, as it makes no sense to
estimate the differences when these are based on random
variation.
In adjusted analysis, depressive symptoms (HR: 2.30; 95%
CI: 1.13–4.69; p=0.02) remained an independent correlate of
adverse events at follow-up in men, whereas there was no
effect in women (Table 3).
DISCUSSION
Depression is an important risk marker for adverse prognosis
in cardiac patients and has also been associated with second-
ary outcomes, including impaired quality of life, poor adher-
ence and rehospitalizations2–7. Given time pressure in clinical
cardiology practice, the availability of brief and valid screening
instruments, such as the PHQ-2 and the PHQ-9, to identify
patients at risk for depression is important as an alternative to
time-consuming, clinical diagnostic interviews13. To our
knowledge, only two studies have examined the prognostic
Table 2. Hazard Ratios, 95% CI and P-values from Adjusted Models
Regressing Depressive Symptoms (Cutoff ≥2) and Other Factors on
Adverse Events*
HR [95% CI] P
Depressive symptoms 1.90 [1.05–3.44] 0.03
Male gender 1.12 [0.59–2.15] 0.73
Age 1.05 [1.02–1.08] 0.002
Multi-vessel disease 1.37 [0.75–2.48] 0.31
Cardiac history† 0.79 [0.42–1.50] 0.47
Hypertension‡ 0.79 [0.42–1.52] 0.48
Hypercholesterolemia§ 0.68 [0.28–1.61] 0.38
Diabetes□ 1.90 [0.94–3.86] 0.08
Smoking¶ 2.44 [1.28–4.65] 0.007
ACE inhibitors 0.99 [0.50–1.97] 0.98
Statins 0.62 [0.28–1.36] 0.23
*Adjusted Cox proportional hazard regression analysis
†Previous MI, PCI or CABG
‡140/90 mmHg or being treated for hypertension
§≥240 mg/dl or being treated for hypercholesterolemia
□Being treated for diabetes
¶Based on the patient’s self-report
Table 3. Hazard Ratios, 95% CI and P-values from Adjusted Models Regressing Depressive Symptoms (Cutoff ≥2) and Other Factors on
Adverse Events, Stratified by Gender*
Men (n=574) Women (n=222)
HR [95% CI] P HR [95% CI] P
Depressive symptoms 2.30 [1.13–4.69] 0.02 1.08 [0.30–3.99] 0.90
Age 1.06 [1.02–1.09] 0.001 1.02 [0.97–1.07] 0.49
Multi-vessel disease 1.40 [0.68–2.91] 0.36 1.01 [0.34–3.03] 0.98
Cardiac history† 0.67 [0.31–1.45] 0.31 1.13 [0.35–3.66] 0.84
Hypertension‡ 0.68 [0.31–1.47] 0.32 1.16 [0.35–3.86] 0.81
Hypercholesterolemia§ 0.88 [0.29–2.68] 0.82 0.55 [0.12–2.54] 0.44
Diabetes□ 2.05 [0.88–4.78] 0.10 1.24 [0.32–4.83] 0.76
Smoking¶ 3.15 [1.48–6.70] 0.003 1.28 [0.32–5.04] 0.73
ACE inhibitors 1.06 [0.48–2.34] 0.88 0.91 [0.21–3.90] 0.90
Statins 0.71 [0.26–1.89] 0.49 0.40 [0.09–1.78] 0.23
*Adjusted Cox proportional hazard regression analysis
†Previous MI, PCI or CABG
‡140/90 mmHg or being treated for hypertension
§≥240 mg/dl or being treated for hypercholesterolemia
□Being treated for diabetes
¶Based on the patient’s self-report
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value of the PHQ in cardiac patients, with both studies using
the PHQ-922,23.
We examined the prognostic value of different cutoffs on the
PHQ-2 in PCI patients. A cutoff ≥3 has been recommended to
screen for depressive disorder in primary care14. However,
other cutoff scores may be considered24, in particular given
that the PHQ-2 to date has been used less in research than the
PHQ-916. Data from the Heart and Soul study showed that a
PHQ-2 cutoff ≥2 exhibited an optimal balance between
sensitivity and specificity for identifying major depression in
cardiac patients, and was comparable to the PHQ-925. The
current study confirms that relatively low levels of depressive
symptoms may identify high-risk patients10, as a cutoff ≥2 on
the PHQ-2 was associated with poor prognosis. Hence, a cutoff
≥2 on the PHQ-2 seems to present the best balance between
sensitivity and specificity as a screening instrument for major
depression in cardiac patients25, but also to have the best
prognostic value.
We also found that the incidence of adverse events was
higher in depressed than non-depressed men, but not in
depressed versus non-depressed women. Given the wide
confidence intervals related to the interaction effect and the
fewer events in women, this finding should be interpreted with
some caution. In the general cardiovascular literature, depres-
sion has been shown to exert a similar prognostic effect in men
and women22,30,31, although some earlier studies reported a
more malignant effect in women32. Differences in the prevalence
of depression could not explain the differential prognostic
influence found in the current study, as men and women did
not differ in depressive symptoms.Womenare generally known to
report more symptoms of depression than men, although this
has been supported in some18,31,33,34, but not all studies of
cardiac patients22.
The results of the current study have implications for
research and clinical practice, and extend those of previous
research, demonstrating that the PHQ-2 may help identify
high-risk patients despite state-of-the-art treatment in inter-
ventional cardiology. The PHQ-2 is a valid and reliable
screening instrument15,24 that can easily be used for research
purposes and in clinical practice due to its brevity. The PHQ-2
is also sensitive to tapping treatment-related changes24,
making it suitable to use as an outcome measure in clinical
and intervention trials. Nevertheless, there is as yet no
evidence to show that intervening against depression has any
benefit on survival35.
The current study has some limitations. First, the number
of clinical events was 47, potentially leading to overfitting of the
adjusted models due the number of covariates included.
Hence, in secondary analyses the power may have been too
low to find a significant effect for depression in women, if
present. Second, a selection bias may have occurred, as
patients who died within the first 30 days post PCI did not
have the opportunity to participate. However, these patients
are more likely to have died due to medical complications than
their psychological profile. In addition, assessment of depressive
symptoms at the time of the index PCI may not be the most
optimal, as symptomsmay reflect the underlying somatic disease
rather than depression4,24. Third, we had no information on the
cause of death. Fourth, we had no information on depression
status prior to the index PCI, the use of psychotropic medication,
participation in cardiac rehabilitation and education, which
could have influenced the results. Fifth, although all patients
were advised to take clopidogrel for at least 6 months, we do not
know if patients took their medication as prescribed, and we
could not control statistically for potential variability in the
duration of clopidogrel therapy. Sixth, hypercholesterolemia
was associated with a reduced risk of poor prognosis both in the
total sample and in women, which seems counterintuitive.
However, hypercholesterolemia was defined as ≥240 mg/dl or
being treated for hypercholesterolemia. Secondary prevention
guidelines advocate that all patients with CAD be prescribed
statin therapy irrespective of whether they have hypercholester-
olemia36. Hence, there is likely a considerable overlap between
the variables statin use and hypercholesterolemia. Finally, it is
possible that the differential prognostic effects of the cutoff scores
≥2 versus≥3 on the PHQ-2may be attributed to anti-depressant
therapy being more prevalent in patients with the higher cutoff.
However, this explanation seems unlikely, given evidence from
large-scale trials in cardiac patients37,38, showing that anti-
depressant therapy may reduce depression but not enhance
survival. Similarly, it is possible that differences in cardiac
medication between the two cutoffs would be responsible for
their differential prognostic effects. Again, we deem this unlikely,
as there is not a consistent pattern for the two cutoffs in terms of
differences in medication use or evidence in the literature to
suggest that depressive symptoms are associated with cardiac
medication, such as beta-blocker39 or statin therapy40.
Despite these potential limitations, this study makes an
important contribution to the literature on depression as a risk
factor for adverse prognosis in cardiac patients. To our
knowledge, it is the first study to examine the prognostic value
of the PHQ-2 in cardiac patients and also the potential
differential effects of the two depressive symptoms contained
within the PHQ-2.
In conclusion, in PCI patients treated with the paclitaxel-
eluting stent the two-item PHQ (cutoff ≥2) was associated with
poor prognosis, with depressed patients having a two-fold
independent risk of adverse events. The PHQ-2 is a brief and
valid measure that can easily be used in clinical practice to
identify patients at risk for depression and adverse health
outcomes. Although our results suggest that depressive symp-
toms may exert a more deleterious effect in men than in women,
this should be confirmed in future studies.
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